Oncoceutics Inc., has partnered with NIH with matters related to its imipridone family of anti-cancer compounds. ONC206 has been studied extensively for several years in models of central nervous system cancers, including high grade gliomas as evaluated by the laboratory of Mark Gilbert, chief of the Neuro-Oncology Branch, Center for Cancer Research, NCI.
How’s this for a paradox: The better cancer centers become at keeping patients alive, the more expensive cancer care becomes. This brutal tradeoff hits harder in rural areas, where the cancer burden is higher and the investigator and clinical trial representation is lower.
